关于发现凝血因子VIIa作为治疗血友病抑制物患者新型治疗药物的回忆。 - Suppr

Recollections on the discovery of factor VIIa as a novel therapeutic agent for hemophiliacs with inhibitors.

作者信息

Kisiel W

机构信息

Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.

出版信息

J Thromb Haemost. 2009 Jul;7(7):1053-6. doi: 10.1111/j.1538-7836.2009.03450.x. Epub 2009 Apr 27.

DOI:10.1111/j.1538-7836.2009.03450.x

PMID:19422444

Abstract

摘要

相似文献

Recollections on the discovery of factor VIIa as a novel therapeutic agent for hemophiliacs with inhibitors.

J Thromb Haemost. 2009 Jul;7(7):1053-6. doi: 10.1111/j.1538-7836.2009.03450.x. Epub 2009 Apr 27.

The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.

Vox Sang. 1999;77 Suppl 1:38-41. doi: 10.1159/000056714.

Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors.

Haemophilia. 2010 Jan;16(1):179-80. doi: 10.1111/j.1365-2516.2009.02095.x. Epub 2009 Aug 24.

Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.

Haemophilia. 1999 Sep;5 Suppl 3:43-9. doi: 10.1046/j.1365-2516.1999.00037.x.

Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA.

Haemophilia. 2009 Jan;15(1):383-5. doi: 10.1111/j.1365-2516.2008.01869.x. Epub 2008 Aug 27.

[Lessons about recombinant activated factor VII. Ten years since its registration for use in hemophilia complicated with inhibitor].

Med Clin (Barc). 2007 Sep 22;129(10):382-6. doi: 10.1157/13110218.

Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders.

BioDrugs. 2008;22(2):121-36. doi: 10.2165/00063030-200822020-00005.

Re: Discordant pair analysis of rFVIIa and pd-aPCC response.

Haemophilia. 2011 Mar;17(2):323-5. doi: 10.1111/j.1365-2516.2010.02405.x.

Clinical efficacy of prothrombin complex concentrates and recombinant factor VIIa in the treatment of bleeding episodes in patients with factor VII and IX inhibitors.

Thromb Res. 1999 Aug 15;95(4 Suppl 1):S31-8. doi: 10.1016/s0049-3848(99)00082-1.

A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.

Vox Sang. 2003 Nov;85(4):290-9. doi: 10.1111/j.0042-9007.2003.00365.x.

引用本文的文献

Recombinant activated factor VII in clinical practice: a 2014 update.

J Thromb Thrombolysis. 2015 Feb;39(2):235-40. doi: 10.1007/s11239-014-1114-1.

Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.

Drug Des Devel Ther. 2010 Jul 21;4:127-37. doi: 10.2147/dddt.s6628.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Recollections on the discovery of factor VIIa as a novel therapeutic agent for hemophiliacs with inhibitors.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

Recollections on the discovery of factor VIIa as a novel therapeutic agent for hemophiliacs with inhibitors.

作者信息

机构信息

出版信息